080 was also able to reverse HLA-mediated suppression of ILT2⁺ CD8⁺ T cells as assessed by degranulation and proinflammatory cytokine secretion. Notably, mice with disseminated tumors had extended median survival when treated with a single dose of TTX-080.

Conclusions TTX-080 reverses HLA-G-mediated suppression of ILT2⁺ and ILT4⁺ immune cells that are found within the tumor microenvironment. Blockade of HLA-G using TTX-080 therefore has the potential to reverse broad immune suppression in patients with advanced solid tumors by reinvigorating CD8⁺ T cells, enhancing NK cytolytic activity, and increasing macrophage phagocytosis.

References